Dong-E-E-Jiao Co. Ltd Posts FY Revenue of RMB5.92 bln, Net Profit RMB1.56 bln

China Resources Pharmaceutical reported FY revenue of RMB5.92 bln and FY net profit attributable of RMB1.56 bln for Dong-E-E-Jiao. The company proposes a cash dividend of RMB12.70 for every 10 shares to all shareholders of Dong-E-E-Jiao.

Introduction:
China Resources Pharmaceutical Group Limited (CRP), a prominent Hong Kong-based investment holding company, recently reported its financial results for Dong-E-E-Jiao, a subsidiary of the company. The subsidiary recorded a remarkable FY revenue of RMB5.92 billion ($914.8 million USD) and a net profit attributable of RMB1.56 billion ($237.1 million USD) [1]. This article delves into CRP's impressive financial performance and its significant role in the pharmaceutical industry.

Company Overview:
CRP is primarily engaged in the research and development, manufacturing, distribution, and retail of pharmaceutical and other healthcare products. The company operates through three main segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, and Pharmaceutical Retail [2]. CRP's Pharmaceutical Distribution segment is the largest contributor to the company's revenue, accounting for approximately 82.6% [3].

Financial Performance:
Despite the impressive FY results reported by Dong-E-E-Jiao, it is important to note that CRP's total revenue for 2023 was $34.61 billion USD, a substantial increase from the previous year's revenue of $34.61 billion USD [2]. This growth suggests that CRP's overall financial performance is strong and diversified.

Dividend Proposal:
As a testament to the company's financial strength, CRP proposed a cash dividend of RMB12.70 for every 10 shares to all shareholders of Dong-E-E-Jiao [1]. This dividend proposal underscores CRP's commitment to rewarding its shareholders and reinvesting in its business.

Conclusion:
China Resources Pharmaceutical Group Limited's impressive financial performance, particularly that of its subsidiary Dong-E-E-Jiao, highlights the company's position as a significant player in the pharmaceutical industry. With a diverse range of operations and a strong financial performance, CRP is well-positioned for continued success.

References:
[1] MarketScreener. (2023, March 31). China-Resources Pharmaceutical Announces KPC Pharmaceuticals FY Results. Retrieved from https://www.marketscreener.com/quote/stock/CHINA-RESOURCES-PHARMACEU-32089762/news/China-Resources-Pharmaceutical-Announces-KPC-Pharmaceuticals-FY-Results-49299110/
[2] Companies Market Cap. (n.d.). China Resources Pharmaceutical Group. Retrieved from https://companiesmarketcap.com/china-resources-pharmaceutical-group/revenue/
[3] PitchBook. (n.d.). China Resources Pharmaceutical Group Overview. Retrieved from https://pitchbook.com/profiles/company/167834-71